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This supplement summarises a symposium that
took place at the 16thECCMID inNice, France, on 2
April 2006. The aim of the symposium was to
address concerns about the changing epidemiol-
ogy of serious bacterial infections, growing bacter-
ial resistance, and the potential means of
alleviating these developments, including the use
of local surveillance, and the introduction of new
antibiotics such as the unique broad-spectrum
cephalosporin with anti-methicillin-resistant Sta-
phylococcus aureus (MRSA) activity, ceftobiprole.
The prevalence of bacterial resistance involving
both Gram-positive and Gram-negative patho-
gens is increasing worldwide. The first article in
this supplement identifies the changing environ-
ment of antimicrobial resistance and provides
advice on combating resistance. The altered epi-
demiology of Gram-positive pathogens, such as
the rise in MRSA rates, illustrates the issue.
Furthermore, outbreaks of community-acquired
and hospital-acquired MRSA have been partic-
ularly troublesome. Responding to such challeng-
ing situations requires appropriate interventions
by the healthcare systems, including improved
infection control measures and selection and use
of appropriate and adequate antibiotic coverage.
Although bacterial resistance has become a global
problem, there are still appreciable geographic
epidemiological differences.
The second article serves to highlight the
importance of regional and local surveillance
and their application for control and treatment
decisions at the local level. For example, MRSA
bacteraemia rates have been found to vary from
<1% in some European countries to approxi-
mately 50% in others. There are also variable
bacterial pathogen rates in different hospitals and
units within hospitals. Therefore, in addition to
global, regional and national benchmarks, local
assessments are essential for individualised treat-
ment decisions. Local antibiograms can also
effectively guide hospital-specific antibiotic poli-
cies and infection control programmes. Because of
the rapidly evolving bacterial picture, ensuring
optimal treatment can be demanding. Therefore,
there is a continuing need for novel antibiotics
that offer new treatment options for serious
bacterial infections and that can overcome cur-
rently known bacterial resistance mechanisms.
The third article in this supplement details the
in-vitro profile of a new b-lactam, ceftobiprole,
with broad-spectrum activity, including MRSA.
This latter activity has been attributed to the
formation of stable inhibitory complexes with
S. aureus penicillin-binding protein 2¢ (2a) by this
novel cephalosporin, an activity not seen with any
other licensed b-lactam. For example, ceftobiprole
MIC90 values for MRSA isolates have generally
been reported at 2 mg ⁄L. In addition, ceftobiprole
has demonstrated potent activity against most
streptococcal species, including penicillin-resist-
ant Streptococcus pneumoniae. Finally, the broad
Gram-negative in-vitro activity of ceftobiprole has
been found to be comparable to that of cefepime,
ceftazidime and piperacillin–tazobactam. As a
segue to the clinical data, results from animal
models that demonstrate potent in-vivo ceftobi-
prole activity consistent with the promising in-
vitro data are presented.
The last article in this supplement introduces
the ceftobiprole clinical development programme
for serious bacterial infections. Dose selection,
pharmacokinetics and safety and tolerability
information from the phase I and II studies are
summarised. Additionally, preliminary results
from a phase III study comparing ceftobiprole
and vancomycin for the treatment of complicated
skin and skin structure infections due to Gram-
positive organisms are presented; these show
comparable efficacy and safety for the two drugs
in the clinically evaluable population. Other
ongoing complicated skin and skin structure
infection, as well as nosocomial and community-
acquired pneumonia, phase III trials conducted to
assess the clinical efficacy and tolerability of
ceftobiprole in a wider range of Gram-positive
and Gram-negative infections are also mentioned.
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